CONMED (CNMD)
(Delayed Data from NYSE)
$73.22 USD
-0.74 (-1.00%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $73.21 -0.01 (-0.01%) 5:22 PM ET
4-Sell of 5 4
B Value B Growth F Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$73.22 USD
-0.74 (-1.00%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $73.21 -0.01 (-0.01%) 5:22 PM ET
4-Sell of 5 4
B Value B Growth F Momentum B VGM
Zacks News
Here's Why You Should Hold on to CONMED (CNMD) Stock for Now
by Zacks Equity Research
CONMED (CNMD) continues to benefit from robust international sales, broad product portfolio and persistent focus on R&D. However, forex remains a woe.
Why Is Conmed (CNMD) Down 0.7% Since Last Earnings Report?
by Zacks Equity Research
Conmed (CNMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Retain CONMED (CNMD) Stock for Now
by Zacks Equity Research
CONMED (CNMD) continues to benefit from broad product portfolio and persistent focus on R&D. However, forex remains a woe.
CONMED (CNMD) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
CONMED's (CNMD) first-quarter results gain from strong performance in General Surgery segment and expansion in margins.
Conmed (CNMD) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Conmed (CNMD) delivered earnings and revenue surprises of 15.91% and 2.60%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Conmed (CNMD) Q1 Earnings Expected to Decline
by Zacks Equity Research
Conmed (CNMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MMSI vs. CNMD: Which Stock Is the Better Value Option?
by Zacks Equity Research
MMSI vs. CNMD: Which Stock Is the Better Value Option?
Want To Retire Early? Learn the Intelligent Investing Secret - March 24, 2020
by Zacks Equity Research
Accomplishing the financial cushion to retire early is a fantasy for most, but bringing that fantasy to reality is not as difficult as it sounds. If you are willing to make some serious lifestyle adjustments, it can be achievable.
Here's Why You Should Hold on to CONMED (CNMD) Stock Now
by Zacks Equity Research
CONMED (CNMD) continues to benefit from robust international sales, broad product portfolio and persistent focus on R&D. However, forex remains a woe.
Coronavirus to Weigh on These 4 Medical Stocks' Q1 Show
by Sreyoshi Mukherjee
The coronavirus pandemic likely to disrupt the first-quarter performances of players in the MedTech space.
Why Is Conmed (CNMD) Down 6.5% Since Last Earnings Report?
by Zacks Equity Research
Conmed (CNMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
XRAY vs. CNMD: Which Stock Is the Better Value Option?
by Zacks Equity Research
XRAY vs. CNMD: Which Stock Is the Better Value Option?
XRAY or CNMD: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
XRAY vs. CNMD: Which Stock Is the Better Value Option?
CONMED (CNMD) Earnings and Revenues Beat Estimates in Q4
by Zacks Equity Research
CONMED's (CNMD) fourth-quarter earnings gain from higher revenues and strong performance in General Surgery segment. However, high long-term debt remains a concern.
Conmed (CNMD) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Conmed (CNMD) delivered earnings and revenue surprises of 1.12% and 0.01%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Medical Products' Earnings Due on Jan 29: ALGN, HOLX & More
by Urmimala Biswas
A series of product launches despite the ongoing regulatory hurdles is likely to favor revenues in the medical products space this earnings season.
Conmed (CNMD) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Conmed (CNMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Invest in Patterson Companies Stock Now
by Zacks Equity Research
Patterson Companies (PDCO) continues to benefit from robust product portfolio, strong prospects in Animal Health unit and strategic buyouts.
Here's Why You Should Retain Pacific Biosciences Stock Now
by Zacks Equity Research
Pacific Biosciences (PACB) continues to gain from innovative product portfolio and Sequel system. However, stiff competition remains a woe.
Here's Why You Should Retain OPKO Health (OPK) Stock for Now
by Zacks Equity Research
OPKO Health (OPK) continues to gain from RAYALDEE and BioReference platforms, and focus on R&D despite operating losses.
HMS Holdings Acquires Nebraska-Based Intrado's Accent Unit
by Zacks Equity Research
The latest deal is likely to boost HMS Holdings' (HMSY) Payment Integrity solutions business.
Here's Why You Should Hold on to Masimo (MASI) Stock Now
by Zacks Equity Research
Masimo (MASI) raises revenue and earnings guidance for 2019.
PDCO vs. CNMD: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
PDCO vs. CNMD: Which Stock Is the Better Value Option?
6 MedTech Stocks That are Set to Beat the Market in 2020
by Trina Mukherjee
Banking on the three key trends, we zero in on six MedTech stocks that are likely to deliver stellar performance in 2020.
Masimo (MASI) Expands Partnership with Texas-Based Drager
by Zacks Equity Research
Masimo (MASI) sees a slew of developments in recent times.